Testing effectiveness (Phase 2)Study completedNCT05287113
What this trial is testing
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Who this might be right for
Head and Neck Cancer
Incyte Biosciences International Sàrl 176